コーパス検索結果 (left1)
通し番号をクリックするとPubMedの該当ページを表示します
1 PHQ-
9 data were available for 614 patients at 3 months and 572 pati
2 Results
Biomarker data were available for 340 patients.
3 Twelve-week surrogate
biomarker data were available for 711 patients.
4 Between 1991 and 1999, genetic and
clinical data were available for 17853 patients with cystic fibrosis,
5 In the combined
cohort,
data were available for 40 patients at baseline and 38 patien
6 Detailed follow-up
colonoscopy data were available for 33 patients.
7 Complete data were available for 110 patients (mean age, 58 years; ran
8 Complete data were available for 172 patients; surgicopathologic findi
9 Complete data were available for 202 patients.
10 Pathologic and PET/
CT data were available for all patients.
11 Baseline
DFT data were available for 717 patients (88.4%).
12 Dexamethasone suppression test (
DST)
data were available for 101 patients.
13 Five-year
echocardiogram data were available for 424 patients after TAVR and 49 after
14 Electrocardiographic data were available for 185 patients.
15 Post-trial
followup data were available for 153 patients (85% of the original coh
16 Complete clinical outcome and
MIC data were available for 421 patients.
17 Complete 12-
month data were available for 193 patients (89%).
18 Week 12
outcome data were available for 132 patients who initiated with mesal
19 At this point,
outcome data were available for 223 patients (mean follow-up 33.3 mon
20 At 145 mg/m2,
PK data were available for 40 patients; 36 were also assessable
21 Prescription data were available for 172 patients, of whom 154 had 'PNES o
22 Response data were available for 35 patients.
23 Surgical data were available for 889 patients.
24 tration versus time (AUC) and total-body clearance (CL(
tb))
data were available for 122 patients (cohort 1, 46 patients;
25 Therapeutic data were available for 55 patients: 39 patients (78%) receiv
26 Thirty-day follow-
up data were available for 393 patients (64%), and 14-day follow
27 therapy for ovarian cancer between 1984 and 1998; follow-
up data were available for 411 patients.
28 Follow-
up data were available for 467 patients with median age of 65 ye
29 Follow-
up data were available for 6026 patients: 2714 (45.0%) had moder
30 Six-month follow-
up data were available for 975 patients (73%).
31 Complete follow-
up data were available for all patients.
32 Follow-
up data were available for all patients.
33 1-
year data were available for 1696 patients in the bivalirudin grou
34 At 3
years,
data were available for 260 patients (77.8%), including 85.6%
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。